BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
search help
Documents 1-3 out of 3 found
  Current Search:  nexavar: 6, sorafenib: 34, tosylate: 74  
70%
PDF
2006_AGEN_10K_full.pdf
smart science.
Forward- looking statements include statements about generating royalty revenue from QS- 21 in the 2010 timeframe, our timelines for performing and completing research, preclinical studies and clinical trials, timelines for releasing data from clinical trials, timelines for initiating new clinical trials, expectations regarding research, preclinical studies,...

author: ayildiz
Matching: nexavar sorafenib Find similar documents More document info

70%
PDF
2006_AGEN_10K_full.pdf page 11


author: ayildiz
duplicates:
http://www.antigenics.com/investors/sec/10k/2006_AGEN_10-K.pdf
Matching: Find similar documents More document info

70%
PDF
printmgr file
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
These forward- looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward- looking statements.
S., Nexavar ® is a registered trademark of Onyx Pharmaceuticals, and Sutent ® is a registered trademark of...

Matching: nexavar sorafenib Find similar documents More document info

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.